An updated natural history model of cervical cancer: Derivation of model parameters

American Journal of Epidemiology

Volumn 180, Issue 5, 2014, Pages 545-555

  Campos, Nicole G ^a   Burger, Emily A ^a,b   Sy, Stephen ^a   Sharma, Monisha ^a,c   Schiffman, Mark ^d   Rodriguez, Ana Cecilia ^e   Hildesheim, Allan ^d   Herrero, Rolando ^e,f   Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Decision analysis; Human papillomavirus; Mathematical models; Uterine cervical neoplasms

Indexed keywords

CANCER; CARCINOGEN; DECISION ANALYSIS; DISEASE CONTROL; DISEASE INCIDENCE; DISEASE PREVALENCE; GENOTYPE; HEALTH POLICY; HISTOLOGY; NUMERICAL MODEL; PARAMETERIZATION; VIRAL DISEASE; WOMENS HEALTH; COST-BENEFIT ANALYSIS; HEALTH RISK; INFECTIOUS DISEASE; PUBLIC HEALTH; SPATIOTEMPORAL ANALYSIS;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE DURATION; ECONOMIC EVALUATION; FEMALE; GENOTYPE; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; MATHEMATICAL MODEL; MEDICAL HISTORY; NONHUMAN; PRECANCER; PREVALENCE; UTERINE CERVIX CANCER; VIRAL CLEARANCE; WART VIRUS; CANCER MORTALITY; CANCER SCREENING; COMPARATIVE EFFECTIVENESS; DECISION TREE; DIET SUPPLEMENTATION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR VIRUS; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

NEW MEXICO; UNITED STATES; COSTA RICA;

HUMAN PAPILLOMAVIRUS;

DECISION ANALYSIS; HUMAN PAPILLOMAVIRUS; MATHEMATICAL MODELS; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ADULT; AGED; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPUTER SIMULATION; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEW MEXICO; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

BETA CAROTENE; WART VIRUS VACCINE;

EID: 84907343355     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu159     Document Type: Article

References (48)

1. Schiffman M. The need for forward-looking decision analyses to guide cervical cancer prevention. Cancer Epidemiol Biomarkers Prev. 2011;20(2): 219-220.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1): 12-19.
3. Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11): 1582-1589.
4. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590): 890-907.
5. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer. 2007; 121(3): 621-632.
6. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine. 2006;24(suppl 3): S3/155-S3/163.
7. Stout NK, Knudsen AB, Kong CY, et al. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics. 2009;27(7): 533-545.
8. Rutter CM, Miglioretti DL, Savarino JE. Bayesian calibration of microsimulation models. J Am Stat Assoc. 2009;104(488): 1338-1350.
9. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: A critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9: 119.
10. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev. 2011; 20(2): 287-296.
11. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353(20): 2158-2168.
12. Kulasingam SL, Havrilesky L, Ghebre R, et al. Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services; 2011.
13. Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol. 2007;166(2): 137-150.
14. Castle PE, Stoler MH, Solomon D, et al. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: An ALTS report. Am J Clin Pathol. 2007;127(5): 805-815.
15. Cox JT, Schiffman M, Solomon D, et al. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188(6): 1406-1412.
16. Kjær SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19): 1478-1488.
17. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101(7): 475-487.
18. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359(8): 821-832.
19. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339: b3884.
20. Goldie SJ, Kim JJ, Kobus K, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine. 2007;25(33): 6257-6270.
21. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, et al. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr. 2007;5: 11.
22. Herrero R, Hildesheim A, Rodríguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 2008;26(37): 4795-4808.
23. Muñoz N, Méndez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190(12): 2077-2087.
24. Rodríguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5): 315-324.
25. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007; 13(2): 559-565.
26. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6): 695-706.
27. Keefe KA, Schell MJ, Brewer C, et al. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 2001;10(10): 1029-1035.
28. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: A retrospective cohort study. Lancet Oncol. 2008;9(5): 425-434.
29. Parkin DM, Whelen SL, Ferlay J, et al. Cancer Incidence in Five Continents. Vols. I-VIII. (IARC Cancer Base no. 7). Lyon, France: International Association of Cancer Registries; 2005.
30. Ries LAG, Melbert D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004.
31. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151(12): 1158-1171.
32. McCrory D, Mather D, Bastian L, et al. Evaluation of Cervical Cytology. (Evidence report/technology assessment no. 5). Rockville, MD: Agency for Health Care Policy and Research, US Department of Health and Human Services; 1999.
33. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, Division of Cancer Control and Population Sciences. SEER Stat Database: Incidence-SEER
34. Regs Research Data + Hurricane Katrina Impacted Louisiana Cases Nov 2011 Sub (1973-2009 Varying)-Linked to County Attributes-Total U.S., 1969-2010 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2012.
35. Wheeler CM, Hunt WC, Cuzick J, et al. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2013;132(1): 198-207.
36. Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer. 2002;87(3): 324-333.
37. Castle PE, Katki HA. Benefits and risks of HPV testing in cervical cancer screening. Lancet Oncol. 2010;11(3): 214-215.
38. Van de Velde N, Boily MC, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: A model-based analysis. J Natl Cancer Inst. 2012;104(22): 1712-1723.
39. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 2006;3(5): e138.
40. French KM, Barnabas RV, Lehtinen M, et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer. 2007;96(3): 514-518.
41. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1): 28-41.
42. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004; 10(11): 1915-1923.
43. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology. 2002;13(6): 631-639.
44. Vänskä S, Auranen K, Leino T, et al. Impact of vaccination on 14 high-risk HPV type infections: A mathematical modelling approach. PLoS One. 2013;8(8): e72088.
45. Dunne EF, Sternberg M, Markowitz LE, et al. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States-National Health and Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact? J Infect Dis. 2011;204(4): 562-565.
46. Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003- 2006. J Infect Dis. 2011;204(4): 566-573.
47. van der Marel J, Quint WG, Schiffman M, et al. Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16. Int J Cancer. 2012;131(6): E946-E953.
48. Kim JJ,Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287(18): 2382-2390.